Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

6 Sökresultat.
Relevans Bedömning Nya först Gamla först

Melanoma Concomitant Medication NCT00110019 - Concomitant Medication Melanoma NCT00110019 E2603 No. 2169

- 2015-03-26 - 1 Formulär, 2 Item-grupper, 29 Dataelement, 2 Språk
Item-grupper: Header, Concomitant Medication
E2603 Concomitant Medication Form Form No. 2169 Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma NCT00110019 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E7D649ED-D8C9-54BD-E034-0003BA3F9857

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Chronic and concomitant medication; Concomitant vaccination (Report Final and Annex Report 2 Final)

- 2020-11-02 - 1 Formulär, 5 Item-grupper, 14 Dataelement, 1 Språk
Item-grupper: Administrative, Chronic and concomitant medication, Chronic and concomitant medication , Concomitant Vaccination, Concomitant Vaccination
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Concomitant Medication SirTac NCT02936388 - Concomitant Medication

- 2017-12-03 - 1 Formulär, 1 Item-grupp, 12 Dataelement, 1 Språk
Item-grupp: Concomitant Medication
Study part: Concomitant Medication. A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma. Provided by Prof. Dr. Ulrich Keilholz, Charité – University of medicine Berlin. EudraCT-Nummer: 2014-002439-32. NCT02936388.

Ethanol-Free Clobetasol Propionate Foam vs Vehicle Foam in Chronic Hand Dermatitis NCT01323673 - Unscheduled Visit; Concomitant Medications; Concomitant Procedures; Adverse Events; General Comments; Subject's Post-Study Questionnaire

- 2019-01-30 - 1 Formulär, 12 Item-grupper, 60 Dataelement, 1 Språk
Item-grupper: Unscheduled Visit, Concomitant Medications, Concomitant Procedures, Adverse Events, General Comments, Subject's Post-Study Questionnaire, 1 - Skin Medicines used in past, 2 - Rate Qualities of Foam, 3 - Rate the Foam, 4 - Compare Foam to Other Types of Skin Medicines, 5 - Likely to be compliant using various types of Medicines, 6 - What do you like or not like about the Foam?
Study ID: 115054 Clinical Study ID: 115054 Study Title: Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01323673 Sponsor: GlaxoSmithKline Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Vehicle / Placebo Trade Name: clobetasol propionate Study Indication: Dermatitis, Chronic

Safety and reactogenicity of booster dose of either an investigational vaccination regimen or DTPw HBVHib 103812 & 104727 - 104727 (DTPW-HBV=HIB-MENAC-TT-016 BST 013 (15/24M)) - Concomitant Vaccination; Medication, Non- serious Adverse Events; Study Conclusion

- 2019-01-22 - 1 Formulär, 8 Item-grupper, 39 Dataelement, 1 Språk
Item-grupper: Concomitant Vaccination, Concomitant Vaccination , Medication, Medication, Non- serious Adverse Event, Non- serious Adverse Event , Study Conclusion , Investigator's signature
Study ID:103812 & 104727 Clinical Study ID:103812 & 104727 Study Title: Study to assess safety and reactogenicity of booster dose of either an investigational vaccination regimen or DTPw-HBV/Hib when administered at 15 to 18 months of age and of a dose of Mencevax ACWY vaccine. Patient Level Data:N/A Clinicaltrials.gov Identifier:N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine Trade Name: Tritanrix HepB/Hiberix Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis

Safety and reactogenicity of booster dose of either an investigational vaccination regimen or DTPw HBVHib 103812 & 104727 - 103812 (DTPW-HBV=HIB-MENAC-TT-014 BST:013&004 (15-18M)) - Medication; Non- Serious Adverse Events; Study Conclusion

- 2019-01-22 - 1 Formulär, 6 Item-grupper, 34 Dataelement, 1 Språk
Item-grupper: Medication, Medication, Non- serious Adverse Event, Non- serious Adverse Event, Study Conclusion, Investigator's signature
Study ID:103812 & 104727 Clinical Study ID:103812 & 104727 Study Title: Study to assess safety and reactogenicity of booster dose of either an investigational vaccination regimen or DTPw-HBV/Hib when administered at 15 to 18 months of age and of a dose of Mencevax ACWY vaccine. Patient Level Data:N/A Clinicaltrials.gov Identifier:N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine Trade Name: Tritanrix HepB/Hiberix Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial